Deciphera Pharmaceuticals Llc Stock Profit Margin
| DCPH Stock | USD 25.36 0.09 0.36% |
Deciphera Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Deciphera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Deciphera Stock. The fundamental analysis module provides a way to measure Deciphera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Deciphera Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | (1.19) | (1.25) |
Deciphera | Profit Margin |
Deciphera Pharmaceuticals LLC Company Profit Margin Analysis
Deciphera Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Deciphera Pharmaceuticals Profit Margin | (1.19) % |
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Deciphera Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Deciphera Pharmaceuticals is extremely important. It helps to project a fair market value of Deciphera Stock properly, considering its historical fundamentals such as Profit Margin. Since Deciphera Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Deciphera Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Deciphera Pharmaceuticals' interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Deciphera Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Deciphera Pharmaceuticals LLC has a Profit Margin of -1.1934%. This is 89.35% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 6.03% lower than that of the firm.
Deciphera Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.Deciphera Pharmaceuticals is currently under evaluation in profit margin category among related companies.
Deciphera Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Deciphera Pharmaceuticals from analyzing Deciphera Pharmaceuticals' financial statements. These drivers represent accounts that assess Deciphera Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Deciphera Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.7B | 3.2B | 567.5M | 1.2B | 1.4B | 968.0M | |
| Enterprise Value | 2.6B | 3.1B | 511.3M | 1.2B | 1.3B | 886.8M |
Deciphera Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 82.23 M | ||||
| Shares Owned By Insiders | 30.02 % | ||||
| Shares Owned By Institutions | 72.29 % | ||||
| Number Of Shares Shorted | 5.75 M | ||||
| Price To Earning | (6.78) X | ||||
| Price To Book | 5.92 X | ||||
| Price To Sales | 12.72 X | ||||
| Revenue | 163.36 M | ||||
| Gross Profit | (62.55 M) | ||||
| EBITDA | (210.96 M) | ||||
| Net Income | (194.94 M) | ||||
| Cash And Equivalents | 383.85 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 25.88 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.02 X | ||||
| Book Value Per Share | 4.36 X | ||||
| Cash Flow From Operations | (146.7 M) | ||||
| Short Ratio | 10.90 X | ||||
| Earnings Per Share | (2.29) X | ||||
| Price To Earnings To Growth | (0.32) X | ||||
| Target Price | 26.38 | ||||
| Number Of Employees | 355 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 2.09 B | ||||
| Total Asset | 473.57 M | ||||
| Retained Earnings | (1.43 B) | ||||
| Working Capital | 280.82 M | ||||
| Current Asset | 70.55 M | ||||
| Current Liabilities | 5.98 M | ||||
| Net Asset | 473.57 M |
About Deciphera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Deciphera Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Deciphera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Deciphera Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Deciphera Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Deciphera Pharmaceuticals' short interest history, or implied volatility extrapolated from Deciphera Pharmaceuticals options trading.
Pair Trading with Deciphera Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Deciphera Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Deciphera Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Deciphera Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Deciphera Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Deciphera Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Deciphera Pharmaceuticals LLC to buy it.
The correlation of Deciphera Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Deciphera Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Deciphera Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Deciphera Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Deciphera Pharmaceuticals Piotroski F Score and Deciphera Pharmaceuticals Altman Z Score analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Deciphera Stock analysis
When running Deciphera Pharmaceuticals' price analysis, check to measure Deciphera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Deciphera Pharmaceuticals is operating at the current time. Most of Deciphera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Deciphera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Deciphera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Deciphera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Deciphera Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.29) | Revenue Per Share 1.92 | Quarterly Revenue Growth 0.329 | Return On Assets (0.28) | Return On Equity (0.56) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.